Related references
Note: Only part of the references are listed.SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
Christian Eichelberg et al.
EUROPEAN UROLOGY (2015)
Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma
Nobuo Shinohara et al.
INTERNATIONAL JOURNAL OF UROLOGY (2015)
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
Matteo Santoni et al.
TARGETED ONCOLOGY (2015)
Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features
Romain Mathieu et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients
Giuseppe Procopio et al.
ONCOLOGY (2015)
Use of Targeted Therapies for Advanced Renal Cell Carcinoma in the Asia-Pacific Region: Opinion Statement From China, Japan, Taiwan, Korea, and Australia
Dingwei Ye et al.
CLINICAL GENITOURINARY CANCER (2014)
Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy
Nils Kroeger et al.
EUROPEAN UROLOGY (2014)
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer
Luis Leon et al.
TARGETED ONCOLOGY (2014)
Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib
Whi-An Kwon et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
M. Santoni et al.
BRITISH JOURNAL OF CANCER (2013)
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Cora N. Sternberg et al.
EUROPEAN JOURNAL OF CANCER (2013)
Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
Takeshi Ueda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y. C. Heng et al.
LANCET ONCOLOGY (2013)
New Insights into the Management of Renal Cell Cancer
Nicolas Pecuchet et al.
ONCOLOGY (2013)
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry
T. Buchler et al.
ANNALS OF ONCOLOGY (2012)
Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
Seong Joon Park et al.
CHEMOTHERAPY (2012)
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
Daniel Keizman et al.
EUROPEAN JOURNAL OF CANCER (2012)
The Role of Genetic Markers in the Management of Prostate Cancer
Atish D. Choudhury et al.
EUROPEAN UROLOGY (2012)
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement
C. Porta et al.
MEDICAL ONCOLOGY (2012)
Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
In-Chang Cho et al.
KOREAN JOURNAL OF UROLOGY (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines
P. K. Julka et al.
BRITISH JOURNAL OF RADIOLOGY (2008)
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
